A 68-year-old woman presents to the Emergency Department with 2 hours of central chest pain. Her ECG shows widespread T-wave inversion in the anterior leads (V2-V6) and troponin I is elevated at 2,850 ng/L (normal <14 ng/L). She has a history of hypertension and hyperlipidaemia. Her observations are: BP 142/86 mmHg, heart rate 88 bpm, oxygen saturation 97% on room air. She is pain-free after sublingual GTN and morphine. What is the GRACE score used to predict in this clinical context?
Q42
A 72-year-old man is reviewed in the heart failure clinic 6 months after diagnosis. He has heart failure with reduced ejection fraction (LVEF 29%) and is currently taking bisoprolol 10 mg once daily, ramipril 10 mg once daily, spironolactone 25 mg once daily, and furosemide 40 mg once daily. He remains breathless on minimal exertion (NYHA class III). His BP is 108/64 mmHg, heart rate 72 bpm in sinus rhythm. Blood tests show: sodium 136 mmol/L, potassium 4.8 mmol/L, creatinine 118 μmol/L (eGFR 52 mL/min/1.73m²), NT-proBNP 1650 ng/L. What is the most appropriate medication change to improve his prognosis?
Q43
A 50-year-old man presents to his GP with intermittent palpitations. He describes episodes of rapid regular heartbeat lasting up to 2 hours, occurring approximately twice per month. He is otherwise well with no chest pain or breathlessness. Examination reveals BP 128/76 mmHg, heart rate 74 bpm regular, BMI 28 kg/m². ECG shows sinus rhythm. He has no past medical history of note. A 24-hour Holter monitor confirms paroxysmal atrial fibrillation with episodes totalling 3 hours. What is his CHA₂DS₂-VASc score?
Q44
A 55-year-old woman with newly diagnosed heart failure and reduced ejection fraction (LVEF 32%) has been started on ramipril and bisoprolol. She remains NYHA class II with mild exertional breathlessness. Her blood pressure is 118/72 mmHg and heart rate 68 bpm. Blood tests show: sodium 138 mmol/L, potassium 4.2 mmol/L, creatinine 95 μmol/L (eGFR 62 mL/min/1.73m²), NT-proBNP 850 ng/L. Echocardiography confirms LVEF 32% in sinus rhythm. She tolerates her current medications well. What is the most appropriate next step to improve her long-term prognosis?
Q45
A 60-year-old man attends for his annual review. He was diagnosed with hypertension 2 years ago and has been taking amlodipine 10 mg once daily. His clinic blood pressure today is 142/88 mmHg. He reports good adherence to medication and has no symptoms. He does not smoke and has a BMI of 26 kg/m². His 24-hour ambulatory blood pressure monitoring shows an average of 138/84 mmHg. Blood tests show eGFR 68 mL/min/1.73m², HbA1c 38 mmol/mol, total cholesterol 5.2 mmol/L. What is the most appropriate next step in his management?
Q46
What is the mechanism of action of sacubitril-valsartan in the treatment of heart failure with reduced ejection fraction?
Q47
A 68-year-old woman presents to the Emergency Department with 90 minutes of central chest pain. ECG shows 3 mm ST-elevation in leads II, III, and aVF with reciprocal ST-depression in leads I and aVL. She is given aspirin 300 mg, ticagrelor 180 mg, and morphine. The nearest primary PCI centre is 90 minutes away by ambulance. She presented 45 minutes after symptom onset. What is the most appropriate management?
Q48
A 76-year-old man presents with increasing breathlessness over the past year. He describes a crescendo-decrescendo systolic murmur heard best at the right upper sternal edge radiating to the carotids. He has had three episodes of exertional syncope in the last 6 months. Echocardiography confirms severe aortic stenosis with aortic valve area 0.6 cm², mean gradient 55 mmHg, and LVEF 48%. He has chronic kidney disease stage 3b and previous stroke 4 years ago with good recovery. What is the most appropriate management?
Q49
A 54-year-old man with ischaemic cardiomyopathy (LVEF 26%) is reviewed in the heart failure clinic. He is on optimal medical therapy including ramipril, bisoprolol, spironolactone, and furosemide. Despite this, he has persistent symptoms (NYHA class II-III). His ECG shows sinus rhythm with heart rate of 88 bpm and QRS duration of 118 ms. Blood pressure is 112/70 mmHg. An implantable cardioverter-defibrillator (ICD) was fitted 18 months ago for primary prevention. What additional therapy should be considered?
Q50
A 59-year-old man with newly diagnosed paroxysmal atrial fibrillation attends for discussion about anticoagulation. He has no other medical history and takes no regular medications. His CHA2DS2-VASc score is 1 (male, age 59) and HAS-BLED score is 0. He is concerned about bleeding risk and asks whether he needs anticoagulation. What is the most appropriate advice?
Cardiology UK Medical PG Practice Questions and MCQs
Question 41: A 68-year-old woman presents to the Emergency Department with 2 hours of central chest pain. Her ECG shows widespread T-wave inversion in the anterior leads (V2-V6) and troponin I is elevated at 2,850 ng/L (normal <14 ng/L). She has a history of hypertension and hyperlipidaemia. Her observations are: BP 142/86 mmHg, heart rate 88 bpm, oxygen saturation 97% on room air. She is pain-free after sublingual GTN and morphine. What is the GRACE score used to predict in this clinical context?
A. 6-month mortality and risk of myocardial infarction or death (Correct Answer)
B. Risk of stroke following acute coronary syndrome
C. Likelihood of benefit from coronary revascularisation
D. Risk of major bleeding on antiplatelet therapy
E. Long-term cardiovascular mortality over 10 years
Explanation: ***6-month mortality and risk of myocardial infarction or death***
- The **GRACE score** (Global Registry of Acute Coronary Events) is a validated tool for risk stratification in **Acute Coronary Syndrome (ACS)**, predicting in-hospital and **6-month mortality**.
- It incorporates variables such as **age**, **heart rate**, **systolic BP**, **creatinine**, and **ST-segment changes** to guide the timing of invasive management.
*Risk of stroke following acute coronary syndrome*
- Stroke risk in the context of atrial fibrillation is typically assessed using the **CHA₂DS₂-VASc** score, not the GRACE score.
- While ACS increases general cardiovascular risk, GRACE specifically focuses on **ischemic events** and **death** rather than neurological complications.
*Likelihood of benefit from coronary revascularisation*
- GRACE determines the **prognostic risk** and urgency of intervention, but it does not specifically measure the physiological benefit of revascularisation itself.
- Decisions on revascularisation benefit are often guided by **angiographic findings**, **fractional flow reserve (FFR)**, or symptoms.
*Risk of major bleeding on antiplatelet therapy*
- Bleeding risk in patients undergoing treatment for ACS is more accurately predicted using the **CRUSADE** or **ACUITY** scores.
- Patients on long-term anticoagulation for other reasons utilize the **HAS-BLED** score to monitor bleeding potential.
*Long-term cardiovascular mortality over 10 years*
- Long-term (10-year) primary prevention risk is assessed using tools like **QRISK3** or the **Framingham Risk Score**.
- The GRACE score is designed for **acute settings** to predict short-to-medium term outcomes (up to 6 months) following an ACS event.
Question 42: A 72-year-old man is reviewed in the heart failure clinic 6 months after diagnosis. He has heart failure with reduced ejection fraction (LVEF 29%) and is currently taking bisoprolol 10 mg once daily, ramipril 10 mg once daily, spironolactone 25 mg once daily, and furosemide 40 mg once daily. He remains breathless on minimal exertion (NYHA class III). His BP is 108/64 mmHg, heart rate 72 bpm in sinus rhythm. Blood tests show: sodium 136 mmol/L, potassium 4.8 mmol/L, creatinine 118 μmol/L (eGFR 52 mL/min/1.73m²), NT-proBNP 1650 ng/L. What is the most appropriate medication change to improve his prognosis?
A. Add digoxin 62.5 mcg once daily
B. Replace ramipril with sacubitril-valsartan (Correct Answer)
C. Increase furosemide to 80 mg once daily
D. Add ivabradine 5 mg twice daily
E. Increase spironolactone to 50 mg once daily
Explanation: ***Replace ramipril with sacubitril-valsartan***
- In patients with **HFrEF (LVEF ≤35%)** who remain symptomatic (NYHA class II-IV) despite optimal therapy with an **ACE inhibitor**, beta-blocker, and MRA, an **ARNI** (Sacubitril-valsartan) is indicated to reduce mortality and hospitalizations.
- This patient meets the criteria with an **LVEF of 29%**, persistent symptoms (NYHA class III), and elevated **NT-proBNP levels**, making this the most evidence-based step for prognostic benefit.
*Add digoxin 62.5 mcg once daily*
- **Digoxin** is primarily used for **symptom control** and to reduce heart failure hospitalizations, but it does not improve long-term survival or **prognosis** in heart failure.
- It is usually reserved for patients who remain symptomatic despite all other **prognostic-altering medications** having been optimized.
*Increase furosemide to 80 mg once daily*
- **Loop diuretics** like furosemide are essential for managing **fluid overload** and congestive symptoms (like breathlessness), but they do not improve long-term **survival** in heart failure.
- While increasing the dose might alleviate current symptoms, it does not address the underlying **pathophysiological progression** or improve the patient's prognosis.
*Add ivabradine 5 mg twice daily*
- **Ivabradine** is indicated for patients in **sinus rhythm** with an LVEF ≤35% and a heart rate **≥70 bpm** (ESC guidelines) or **≥75 bpm** (NICE guidelines) despite maximum tolerated beta-blockade.
- Although this patient is in sinus rhythm with a heart rate of 72 bpm, switching to an **ARNI** takes clinical precedence due to its superior **mortality benefit** profile as a foundational treatment in GDMT.
*Increase spironolactone to 50 mg once daily*
- This patient is already on a maintenance dose of **spironolactone**, and while the dose could theoretically be increased, it carries a significant risk of **hyperkalemia** and worsening renal function.
- Substituting the ACE inhibitor for an **ARNI** provides a more robust, evidenced-based survival benefit compared to solely up-titrating the **MRA** at this stage of therapy.
Question 43: A 50-year-old man presents to his GP with intermittent palpitations. He describes episodes of rapid regular heartbeat lasting up to 2 hours, occurring approximately twice per month. He is otherwise well with no chest pain or breathlessness. Examination reveals BP 128/76 mmHg, heart rate 74 bpm regular, BMI 28 kg/m². ECG shows sinus rhythm. He has no past medical history of note. A 24-hour Holter monitor confirms paroxysmal atrial fibrillation with episodes totalling 3 hours. What is his CHA₂DS₂-VASc score?
A. 0
B. 4
C. 1 (Correct Answer)
D. 2
E. 3
Explanation: ***1***
- The CHA₂DS₂-VASc score assesses **stroke risk** in patients with **atrial fibrillation**. While this 50-year-old male has no history of **CHF**, **hypertension**, **diabetes**, **stroke/TIA**, or **vascular disease**, and is not aged 65-74 or ≥75.
- However, for male patients with **atrial fibrillation**, a score of **1** is often considered a threshold for discussing **oral anticoagulation** in clinical practice, even with a calculated score of 0, especially for those aged **50-64**, reflecting a low but non-zero risk.
*0*
- This score would imply a very low risk of **thromboembolism** in a patient without atrial fibrillation, or one where anticoagulation is generally not warranted.
- For a male patient with confirmed **atrial fibrillation**, even in the absence of other comorbidities, a score of **0** is generally considered too low for an accurate assessment of **stroke risk** in most guidelines guiding anticoagulation decisions.
*4*
- A score of **4** would indicate a very high risk, typically requiring a history of **stroke/TIA** (2 points) along with two or more additional risk factors like **hypertension** or **diabetes**.
- The patient's history shows no such significant **comorbidities** or prior thromboembolic events.
*2*
- A score of **2** is usually assigned to patients with a history of **stroke/TIA** (2 points) or those **aged ≥75 years** (2 points).
- The patient is only **50 years old** and has no past medical history of **thromboembolism**, making a score of 2 inapplicable.
*3*
- This score would typically be seen in patients with multiple risk factors, for instance, **age 65-74** (1 point) combined with two other risk factors such as **hypertension** (1 point) and **diabetes** (1 point).
- Given the patient's young age and absence of any listed **comorbidities**, a score of 3 is not supported.
Question 44: A 55-year-old woman with newly diagnosed heart failure and reduced ejection fraction (LVEF 32%) has been started on ramipril and bisoprolol. She remains NYHA class II with mild exertional breathlessness. Her blood pressure is 118/72 mmHg and heart rate 68 bpm. Blood tests show: sodium 138 mmol/L, potassium 4.2 mmol/L, creatinine 95 μmol/L (eGFR 62 mL/min/1.73m²), NT-proBNP 850 ng/L. Echocardiography confirms LVEF 32% in sinus rhythm. She tolerates her current medications well. What is the most appropriate next step to improve her long-term prognosis?
A. Add spironolactone 25 mg once daily (Correct Answer)
B. Add digoxin 125 mcg once daily
C. Replace ramipril with sacubitril-valsartan
D. Add ivabradine 5 mg twice daily
E. Add furosemide 40 mg once daily
Explanation: ***Add spironolactone 25 mg once daily***
- In patients with **HFrEF** (LVEF ≤ 35%) who remain symptomatic (NYHA class II) despite an **ACE inhibitor** (ramipril) and a **beta-blocker** (bisoprolol), a **Mineralocorticoid Receptor Antagonist (MRA)** such as spironolactone is the next cornerstone therapy to improve long-term prognosis and survival.
- This patient meets the safety criteria for MRA initiation, with a **potassium of 4.2 mmol/L (< 5.0 mmol/L)** and an **eGFR of 62 mL/min/1.73m² (> 30 mL/min/1.73m²),** and is tolerating current medications well.
*Add digoxin 125 mcg once daily*
- **Digoxin** is primarily used for **symptom control** (reducing hospitalizations) in patients with heart failure who remain symptomatic despite optimal therapy, or for rate control in atrial fibrillation.
- Unlike MRAs, it has **no proven mortality benefit** in heart failure with reduced ejection fraction, making it less suitable as the *next step to improve long-term prognosis*.
*Replace ramipril with sacubitril-valsartan*
- While **sacubitril-valsartan (ARNI)** is a cornerstone therapy for HFrEF that replaces an ACE inhibitor or ARB, current guidelines typically recommend initiating **four-pillar therapy** sequentially.
- For a patient stable on an ACEi and beta-blocker and still symptomatic, the standard progression often involves adding an **MRA** and an **SGLT2 inhibitor** before switching the ACEi, especially if the ACEi is well-tolerated.
*Add ivabradine 5 mg twice daily*
- **Ivabradine** is indicated in symptomatic HFrEF patients who are in **sinus rhythm** with a **heart rate ≥ 70 bpm** (or ≥ 75 bpm depending on specific guidelines) despite optimal beta-blocker therapy.
- This patient's current heart rate is **68 bpm**, which is below the threshold for initiating ivabradine therapy for heart failure.
*Add furosemide 40 mg once daily*
- **Furosemide** is a loop diuretic primarily used for **symptomatic relief** of fluid overload and congestion, such as significant dyspnea or edema; the patient currently only has mild exertional breathlessness.
- While important for managing fluid balance and symptoms, diuretics like furosemide have **not been shown to reduce mortality** or improve long-term prognosis in HFrEF; they are not considered a
Question 45: A 60-year-old man attends for his annual review. He was diagnosed with hypertension 2 years ago and has been taking amlodipine 10 mg once daily. His clinic blood pressure today is 142/88 mmHg. He reports good adherence to medication and has no symptoms. He does not smoke and has a BMI of 26 kg/m². His 24-hour ambulatory blood pressure monitoring shows an average of 138/84 mmHg. Blood tests show eGFR 68 mL/min/1.73m², HbA1c 38 mmol/mol, total cholesterol 5.2 mmol/L. What is the most appropriate next step in his management?
A. Add ramipril and arrange review in 4 weeks
B. Add indapamide and review in 4 weeks
C. Increase amlodipine to 15 mg once daily
D. Continue current therapy and review in 12 months (Correct Answer)
E. Switch amlodipine to doxazosin
Explanation: ***Continue current therapy and review in 12 months***
- For patients under **80 years of age**, the target **ambulatory blood pressure monitoring (ABPM)** average is **<135/85 mmHg**; this patient's reading of 138/84 mmHg is borderline and does NOT strictly require treatment escalation.
- Given he has no **target organ damage** (eGFR and HbA1c are normal) and his **clinic blood pressure** is close to the <140/90 mmHg target, maintenance of current therapy is the most appropriate conservative step.
*Add ramipril and arrange review in 4 weeks*
- Adding an **ACE inhibitor** is considered Step 2 of the **NICE hypertension guidelines**, but it is unnecessary if the patient is already near his personal target without evidence of complications.
- This intervention would be more appropriate if the blood pressure remained significantly elevated or if there were signs of **albuminuria** or **chronic kidney disease**.
*Add indapamide and review in 4 weeks*
- **Thiazide-like diuretics** are generally considered as part of Step 3 therapy (combined with an ACEi/ARB and CCB) or Step 2 for specific patient profiles.
- It is inappropriate to add a third-line class of medication when the patient's blood pressure is already well-controlled on a **calcium channel blocker** alone.
*Increase amlodipine to 15 mg once daily*
- The **maximum licensed dose** of **amlodipine** for hypertension is **10 mg** once daily; exceeding this dose is not standard clinical practice.
- Increasing the dose beyond 10 mg significantly increases the risk of side effects like **pedal edema** without providing a proportional benefit in blood pressure reduction.
*Switch amlodipine to doxazosin*
- **Doxazosin**, an alpha-blocker, is typically reserved as Step 4 therapy for **resistant hypertension** and is not a first-line alternative to a calcium channel blocker.
- Switching medications in a patient who is achieving near-target results and tolerating his current **monotherapy** well would be clinically counterproductive.
Question 46: What is the mechanism of action of sacubitril-valsartan in the treatment of heart failure with reduced ejection fraction?
A. Inhibits neprilysin enzyme and blocks angiotensin II receptors (Correct Answer)
B. Inhibits ACE enzyme and blocks aldosterone receptors
C. Enhances natriuretic peptide activity and inhibits renin release
D. Blocks angiotensin II receptors and inhibits aldosterone synthesis
E. Inhibits neprilysin enzyme and ACE enzyme simultaneously
Explanation: ***Inhibits neprilysin enzyme and blocks angiotensin II receptors*** - **Sacubitril** is a prodrug that inhibits **neprilysin**, an enzyme responsible for degrading **natriuretic peptides** (ANP/BNP), thereby enhancing vasodilation and natriuresis. - **Valsartan** is an **angiotensin II receptor blocker (ARB)** that counteracts the RAAS activation and potential increase in angiotensin II caused by neprilysin inhibition.*Inhibits ACE enzyme and blocks aldosterone receptors* - This describes the mechanism of an **ACE inhibitor** combined with a **Mineralocorticoid Receptor Antagonist (MRA)** like spironolactone. - **Sacubitril-valsartan** does not inhibit the **Angiotensin-Converting Enzyme (ACE)** and is actually contraindicated for use with it due to **angioedema** risk.*Enhances natriuretic peptide activity and inhibits renin release* - While it enhances **natriuretic peptides**, the drug does not directly inhibit **renin release**; renin levels may actually increase due to feedback loops. - **Direct Renin Inhibitors** like **Aliskiren** are the primary agents used to block renin production directly.*Blocks angiotensin II receptors and inhibits aldosterone synthesis* - Though it blocks **AT1 receptors**, it does not specifically target the **aldosterone synthase** enzyme to inhibit synthesis. - Reductions in **aldosterone** are a secondary downstream effect of RAAS blockade rather than the primary dual-mechanism of this specific combination.*Inhibits neprilysin enzyme and ACE enzyme simultaneously* - Inhibiting both enzymes simultaneously was the mechanism of **Omapatrilat**, which was never approved due to severe risks of **life-threatening angioedema**. - To avoid this risk, **Sacubitril** must be paired with an **ARB (Valsartan)** rather than an ACE inhibitor, requiring a 36-hour washout period between treatments.
Question 47: A 68-year-old woman presents to the Emergency Department with 90 minutes of central chest pain. ECG shows 3 mm ST-elevation in leads II, III, and aVF with reciprocal ST-depression in leads I and aVL. She is given aspirin 300 mg, ticagrelor 180 mg, and morphine. The nearest primary PCI centre is 90 minutes away by ambulance. She presented 45 minutes after symptom onset. What is the most appropriate management?
A. Arrange immediate transfer for primary PCI (Correct Answer)
B. Administer thrombolysis and transfer for angiography
C. Administer thrombolysis and arrange transfer only if failed reperfusion
D. Observe with serial ECGs and troponins
E. Arrange urgent but non-emergency transfer for angiography within 24 hours
Explanation: ***Arrange immediate transfer for primary PCI***
- This patient presents with a **ST-elevation myocardial infarction (STEMI)**, characterized by chest pain and **ST-elevation in leads II, III, and aVF** (inferior STEMI) with reciprocal changes.
- Primary PCI is the preferred reperfusion strategy if it can be performed within **120 minutes** of the patient presenting to a facility that could offer fibrinolysis. Given the 90-minute transfer time, this falls within the recommended window.
*Administer thrombolysis and transfer for angiography*
- **Thrombolysis** (fibrinolysis) is typically reserved for situations where primary PCI cannot be performed within the **120-minute target**, or within the first 12 hours of symptom onset if PCI is not available.
- While a transfer for angiography post-thrombolysis (pharmacoinvasive strategy) is recommended, the initial choice of thrombolysis over a feasible primary PCI is not optimal due to higher bleeding risks.
*Administer thrombolysis and arrange transfer only if failed reperfusion*
- Current guidelines recommend a **pharmacoinvasive strategy** for all patients who undergo thrombolysis, meaning transfer for angiography should occur regardless of perceived reperfusion success, typically within 2-24 hours.
- Administering thrombolysis when **primary PCI is logistically achievable** within the recommended timeframe is suboptimal and exposes the patient to unnecessary risks of bleeding and stroke.
*Observe with serial ECGs and troponins*
- **Observation** with serial ECGs and troponins is appropriate for patients with suspected acute coronary syndrome but without persistent ST-elevation (e.g., NSTEMI or unstable angina).
- For **STEMI**, immediate reperfusion (PCI or thrombolysis) is crucial to minimize **myocardial damage** and improve patient outcomes, as time is muscle.
*Arrange urgent but non-emergency transfer for angiography within 24 hours*
- A non-emergency transfer for angiography within 24 hours is typically indicated for patients with **NSTEMI** and high-risk features, or after successful thrombolysis for STEMI.
- For an acute STEMI, delaying definitive reperfusion beyond the acute phase significantly increases the risk of **myocardial necrosis**, **heart failure**, and other complications.
Question 48: A 76-year-old man presents with increasing breathlessness over the past year. He describes a crescendo-decrescendo systolic murmur heard best at the right upper sternal edge radiating to the carotids. He has had three episodes of exertional syncope in the last 6 months. Echocardiography confirms severe aortic stenosis with aortic valve area 0.6 cm², mean gradient 55 mmHg, and LVEF 48%. He has chronic kidney disease stage 3b and previous stroke 4 years ago with good recovery. What is the most appropriate management?
A. Medical management with diuretics and ACE inhibitor
B. Surgical aortic valve replacement
C. Refer for transcatheter aortic valve implantation (TAVI) assessment (Correct Answer)
D. Balloon aortic valvuloplasty
E. Conservative management with symptom monitoring
Explanation: ***Refer for transcatheter aortic valve implantation (TAVI) assessment***
- The patient has **symptomatic severe aortic stenosis** (AVA 0.6 cm², mean gradient 55 mmHg) with symptoms like **exertional syncope**, which indicates a dire prognosis and requires intervention to improve survival.
- Given the patient's age (76), significant **co-morbidities** like **CKD stage 3b** and a history of **stroke**, he is considered high-risk for surgical aortic valve replacement (SAVR), making **TAVI** the preferred or highly considered option after a **Heart Team** assessment.
*Medical management with diuretics and ACE inhibitor*
- Medical therapy, including diuretics, primarily provides **symptomatic relief** but does not address the mechanical obstruction of the aortic valve or improve the **overall prognosis** of severe symptomatic AS.
- **ACE inhibitors** should be used with extreme caution or avoided in severe aortic stenosis due to the risk of precipitating **hypotension** given the fixed cardiac output and preload dependence.
*Surgical aortic valve replacement*
- While **SAVR** is a definitive treatment, the patient's advanced age and multiple **co-morbidities** (CKD stage 3b, prior stroke) place him at a higher **surgical risk** for open-heart surgery.
- Current guidelines recommend a **Heart Team** evaluation to weigh the risks and benefits of SAVR versus TAVI, with TAVI often favored for elderly, high-risk patients.
*Balloon aortic valvuloplasty*
- **Balloon aortic valvuloplasty (BAV)** offers only **temporary symptomatic relief** and is associated with a high rate of **restenosis** within months, making it unsuitable as a definitive long-term treatment.
- BAV is typically reserved as a **bridge to definitive TAVI or SAVR** in hemodynamically unstable patients, or for palliation in patients who are not candidates for valve replacement.
*Conservative management with symptom monitoring*
- **Conservative management** is inappropriate for symptomatic severe AS, as symptoms like **syncope** signify a critical stage with a very poor prognosis (e.g., 50% 2-year mortality) if left untreated.
- Delaying intervention increases the risk of **sudden cardiac death** and irreversible myocardial damage, thereby missing the opportunity to improve survival and quality of life.
Question 49: A 54-year-old man with ischaemic cardiomyopathy (LVEF 26%) is reviewed in the heart failure clinic. He is on optimal medical therapy including ramipril, bisoprolol, spironolactone, and furosemide. Despite this, he has persistent symptoms (NYHA class II-III). His ECG shows sinus rhythm with heart rate of 88 bpm and QRS duration of 118 ms. Blood pressure is 112/70 mmHg. An implantable cardioverter-defibrillator (ICD) was fitted 18 months ago for primary prevention. What additional therapy should be considered?
A. Add ivabradine 5 mg twice daily (Correct Answer)
B. Add digoxin 62.5 mcg once daily
C. Upgrade ICD to cardiac resynchronisation therapy defibrillator (CRT-D)
D. Add hydralazine and isosorbide dinitrate
E. Increase bisoprolol dose
Explanation: ***Add ivabradine 5 mg twice daily***- **Ivabradine** is indicated for patients with HFrEF (LVEF ≤35%) in **sinus rhythm** with a resting heart rate **≥70 bpm** who remain symptomatic (NYHA class II-IV) despite optimal, maximally tolerated beta-blocker therapy.- This patient perfectly fits these criteria, having a **LVEF of 26%**, being in **sinus rhythm** with a heart rate of **88 bpm**, and remaining **symptomatic** (NYHA class II-III) on optimal medical therapy including bisoprolol.*Add digoxin 62.5 mcg once daily*- **Digoxin** is generally considered for symptomatic relief in patients with persistent heart failure, particularly those with concomitant **atrial fibrillation** and a rapid ventricular response, or those who remain symptomatic despite optimal guideline-directed medical therapy.- While it may reduce heart failure hospitalizations, it has not shown a **mortality benefit** in patients with HFrEF in sinus rhythm, unlike ivabradine in the specific subgroup.*Upgrade ICD to cardiac resynchronisation therapy defibrillator (CRT-D)*- **Cardiac resynchronisation therapy (CRT)** is indicated for patients with symptomatic HFrEF (LVEF ≤35%) and a significantly widened **QRS duration**, typically **≥130 ms** with LBBB morphology, or **≥150 ms** for non-LBBB.- The patient's **QRS duration of 118 ms** is below the generally accepted threshold for initiating CRT, making this option currently unsuitable.*Add hydralazine and isosorbide dinitrate*- This combination is primarily recommended for **African-American/Caribbean patients** with moderate-to-severe HFrEF who remain symptomatic despite optimal medical therapy, or for patients of any ethnicity who are **intolerant to ACE inhibitors or ARBs**.- There is no mention of the patient's ethnicity, and he is currently tolerating **ramipril** (an ACE inhibitor), so this combination is not the first-line additional therapy.*Increase bisoprolol dose*- The patient is stated to be on **optimal medical therapy**, which implies that his **bisoprolol** dose has been titrated to the maximum tolerated dose or target dose.- Despite this, his heart rate is still **88 bpm**, suggesting that further increasing the bisoprolol dose might be limited by side effects like hypotension (current BP 112/70 mmHg) or bradycardia, or it has already reached its maximal tolerated therapeutic effect; ivabradine offers a different mechanism for heart rate reduction.
Question 50: A 59-year-old man with newly diagnosed paroxysmal atrial fibrillation attends for discussion about anticoagulation. He has no other medical history and takes no regular medications. His CHA2DS2-VASc score is 1 (male, age 59) and HAS-BLED score is 0. He is concerned about bleeding risk and asks whether he needs anticoagulation. What is the most appropriate advice?
A. Anticoagulation is not indicated; aspirin 75 mg daily is sufficient
B. Anticoagulation is not indicated; no antithrombotic therapy needed
C. Anticoagulation with a DOAC should be offered as it reduces stroke risk (Correct Answer)
D. Anticoagulation should be deferred until CHA2DS2-VASc score reaches 2
E. Aspirin and clopidogrel dual therapy is the preferred option
Explanation: ***Anticoagulation with a DOAC should be offered as it reduces stroke risk***- For **males with a CHA2DS2-VASc score of 1**, guidelines (e.g., ESC/ACC/AHA) recommend considering or offering oral anticoagulation to reduce the risk of **thromboembolic stroke**.- **Direct Oral Anticoagulants (DOACs)** are generally preferred over warfarin for most patients due to their efficacy, ease of use, and favorable safety profile, particularly a lower risk of **intracranial hemorrhage**.*Anticoagulation is not indicated; aspirin 75 mg daily is sufficient*- **Aspirin** monotherapy is **not recommended** for stroke prevention in atrial fibrillation as it has been shown to be significantly less effective than oral anticoagulants.- The **bleeding risk** of aspirin in this context is similar to that of oral anticoagulants, but without the comparable benefit in **stroke reduction**.*Anticoagulation is not indicated; no antithrombotic therapy needed*- While a CHA2DS2-VASc score of 0 for males generally means no antithrombotic therapy, a score of **1 indicates an increased stroke risk** where the benefits of anticoagulation typically outweigh the risks.- Current guidelines differentiate a score of 0 (truly low risk) from a score of 1, where **anticoagulation should be discussed** and often initiated.*Anticoagulation should be deferred until CHA2DS2-VASc score reaches 2*- Delaying anticoagulation for a patient with a CHA2DS2-VASc score of 1 (male) means missing an opportunity for **early stroke prevention**, as their risk is already elevated.- Though anticoagulation is "recommended" at a score of 2 or more, it is "considered" or **offered** at a score of 1, making immediate discussion and offering appropriate.*Aspirin and clopidogrel dual therapy is the preferred option*- **Dual antiplatelet therapy (DAPT)** with aspirin and clopidogrel is **ineffective** for stroke prevention in non-valvular atrial fibrillation compared to oral anticoagulation.- DAPT also significantly **increases the risk of major bleeding** compared to oral anticoagulants, without offering superior protection against **cardioembolic strokes**.
